| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_412d5122114a1e48e28e0a669ac63676
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dbc99b1f59f856e805e908b38b242d8d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c06d114257182ee7efd4c696c5fdb836
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c138baf7471032dadc178a21dc495eeb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_434581794b7b0890c2e23f8bd64f254b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e8045218ef6ca70680975a8fe94f795e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2799-027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-47 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 |
| filingDate |
1998-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce7d69a7e8f0f23ca7ff9227d6b217b2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_969923f297180192a159cfeb72d2a1e9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_082ce38f6f2e082a7b911f20a56483fa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_22b4a5f006e9d489d59dd4f7078d1031
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3bae58ca959601c611c6e24a790a2bae |
| publicationDate |
1999-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-9903883-A1 |
| titleOfInvention |
Compositions and methods based upon the tuberous sclerosis-1 (tsc1) gene and gene product |
| abstract |
The present invention is directed to a tumor suppressor protein which has been designated hamartin and to the gene, TSC1, which encodes this protein. Mutations in the gene have been found to be associated with certain types of tuberous sclerosis and this has served as a basis for a diagnostic method designed to identify patients that have, or are likely to develop, symptoms associated with this disease. The introduction of the TSC1 gene and subsequent expression of hamartin into cells may be used as a means for treating tuberous sclerosis and other conditions characterized by abnormal cellular growth. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6620615-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0064941-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0064941-A2 |
| priorityDate |
1997-07-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |